text.skipToContent text.skipToNavigation

What are pyrogens and endotoxins?

Pyrogens are fever-inducing substances primarily derived from microorganisms such as bacteria, viruses, yeasts, molds, or chemical substances, e.g. primary packaging materials. Pyrogens entering the bloodstream may interact with the host immune system to cause inflammation, fever, chills, shock and, in severe cases, death.

Pyrogens include membrane-derived compounds like lipid-polysaccharides (LPS), flagellin, peptidoglycans, lipids, proteins, etc. They are often heat stable and therefore difficult to remove during manufacturing. The most potent type of pyrogens are bacterial endotoxins which are derived from the cell wall of gram-negative bacteria. Pyrogens that derive from microorganisms other than gram-negative bacterial are collectively referred to as non-endotoxin pyrogens (NEPs).

There are a variety of methods that can be used to detect pyrogens: The traditional qualitative approach has been the rabbit pyrogen test (RPT), which involves measuring the body temperature increase in rabbits following injection of a product potentially containing pyrogens. The monocyte activation test (MAT) was introduced as a sustainable, in vitro alternative to the use of experimental animals. The MAT is based on measuring the release of pro-inflammatory cytokines from cultured human blood monocytes in response to pyrogenic contaminants. MAT kits, such as the PyroCell® MAT System, which measure release of IL-6 are especially useful early in drug development when the presence of all pyrogens should be examined, and testing is not focused specifically on endotoxins.

Bacterial endotoxins are the most potent pyrogenic contaminants and are ubiquitous. Thus, we must try to keep the endotoxin levels as low as possible for all injectable drugs and implantable medical devices. The bacterial endotoxins test (BET) has widely replaced the RPT for pharmaceutical and biotechnology products. Traditional BET using Limulus amebocyte lysate (LAL) tests contain specialized blue blood cells from the wild Atlantic horseshoe crab, Limulus polyphemus, as a component because they react to the presence of endotoxins in a way that can be measured and quantitated. (Similarly, tests available in Asia include cells from an Asian horseshoe crab species, Tachypleus spp., and are called TAL assays.) Sustainable tests, using a recombinant version of the first enzyme in the LAL clotting cascade, such as the PyroGene® rFC Assay, do not rely on the blood of horseshoe crabs. The use of an alternative method reduces the demand on a natural resource and can help meet supply chain sustainability initiatives. They are gaining usage across the globe as companies seek to reduce their reliance on natural resources.


Monocyte Activation Test

With PyroCell® Monocyte Activation Tests (MAT) we can eliminate the reliance on rabbit-based pyrogen testing, helping to ensure drug product safety and compliance. 

Learn about MAT

Run assays with the right reader

Learn about conducting traditional kinetic LAL Assays and recombinant Factor C technology in one easy-to-use instrument. Find out more about Lonza's Nebula® Readers. 

Nebula® Readers

Automation in the testing lab

Implementing the PyroTec® PRO Automated Robotic Solution can reduce the potential for human error and enhance the accuracy, reliability and traceability of results. 

PyroTec® PRO

Learn in the QC Insider® Toolbox

The QC Insider® Toolbox is a vast library of tech tips, white papers, and e-learning modules designed to help you with your pyrogen and endotoxin testing program.

Become a QC Insider®

Topics in endotoxin testing

BET and test types


The bacterial endotoxin test (BET) is a critical part of quality control (QC) testing. Testing products for the presence of bacterial endotoxins is a fundamental safety requirement in the pharmaceutical and biomedical industries and is performed on raw and in-process materials and for the final release of injectable or implantable products. These QC tests must comply with regulatory requirements enforced by global regulatory agencies.

The Limulus amebocyte lysate (LAL) assay was first developed in the 1960s and commercialized as a BET in the U.S. in the 1970s. The LAL assay is formulated using specialized blood cells, or amebocytes, obtained from the blue blood of Atlantic horseshoe crabs. The amebocytes function as the crab’s only immune defense: a blood coagulation system. After encountering foreign substances including endotoxin, amebocytes generate clots that immobilize and kill the pathogens.

Even minimal amounts of endotoxin, less than a billionth of a gram, can trigger this immune response. This occurs via a complex clotting cascade, which has been extensively investigated since the LAL assay was first developed.

The first enzyme in this cascade is the Factor C (FC) enzyme (the biosensor), which binds to the hydrophobic Lipid A component of the LPS molecule to initiate a cascade of enzymatic reactions that result in the formation of a blood clot. LAL testing takes advantage of this endotoxin-sensitive clotting response to produce a BET assay that is reliable, sensitive and specific.

As LAL testing relies on harvesting the blood of wild horseshoe crabs, the conservation of horseshoe crab populations is a key priority. In the U.S., a variety of conservation initiatives have been widely successful in ensuring sustainable harvesting practices. However, the situation is more serious in Asia, where unsustainable blood harvesting practices for TAL production are causing serious population declines.

These considerations have contributed to the development of alternative BET methods that do not rely on harvested crab blood such as the recombinant Factor C (rFC) assay. These assays utilize a cloned version of the Factor C enzyme. When activated in the presence of endotoxin, Factor C cleaves a fluorescent substrate creating a signal that is measured in the rFC assay.

In total, four main types of BET methods have been developed based on the principles of LAL testing. They all have important applications in QC testing during the manufacture of parenteral medicines and injectable devices.